about
A single amino acid determines preference between phospholipids and reveals length restriction for activation of the S1P4 receptorUp-regulation of the angiotensin II type 1 receptor by the MAS proto-oncogene is due to constitutive activation of Gq/G11 by MASbeta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulationBeta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxisDefining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptorAllostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapesBuilding a new conceptual framework for receptor heteromersMetabolism meets immunity: The role of free fatty acid receptors in the immune systemStructural and biophysical characterisation of G protein-coupled receptor ligand binding using resonance energy transfer and fluorescent labelling techniquesSelective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activationPalmitoylation regulates regulator of G-protein signaling (RGS) 16 function. II. Palmitoylation of a cysteine residue in the RGS box is critical for RGS16 GTPase accelerating activity and regulation of Gi-coupled signallingPalmitoylation regulates regulators of G-protein signaling (RGS) 16 function. I. Mutation of amino-terminal cysteine residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an internal cysteine residueHigh-content assays for ligand regulation of G-protein-coupled receptorsSrc-mediated RGS16 tyrosine phosphorylation promotes RGS16 stabilityUncovering the pharmacology of the G protein-coupled receptor GPR40: high apparent constitutive activity in guanosine 5'-O-(3-[35S]thio)triphosphate binding studies reflects binding of an endogenous agonistMorphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation
P50
Q21093656-99801000-257F-48CD-A377-B48082E94847Q24317202-F32F7040-EECF-4975-A804-08539EE9A2F8Q24324243-3E94BB33-9804-411F-99BD-7C54E992B294Q24337549-379174FE-1067-4D10-B518-D79DC851F982Q24338567-7F876F83-7B38-409A-B454-DE729FA787ABQ24633877-0BE0F8A9-F1D6-44C5-B669-EF0383D20809Q24644975-DE9C0460-7F75-4BBE-8A71-1AF00FE6ECAFQ26752828-C241683C-C05F-4BE5-B62F-AC96FFCA81ADQ27022035-DFDC0C15-BD75-4082-B860-694EA6FDBA7BQ28179746-873810EA-7CB2-45E7-9FCE-353BBF387966Q28184243-71A223FF-CD9F-4CCD-9BCE-C1A13497957CQ28184264-02FFA606-5A7E-4A4A-BF04-E81395A6D0ACQ28185834-8CEFA5D4-C338-487D-A3A3-4F23D9BE8FAFQ28209910-EA0B4FA9-F7FE-4200-8351-52A1498152C8Q28281562-2C1300D4-E5EB-4D91-877A-49A8E55D5A5AQ28290869-16017ABB-8133-4027-AD67-EE884D102BEF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Graeme Milligan
@ast
Graeme Milligan
@en
Graeme Milligan
@es
Graeme Milligan
@nl
Graeme Milligan
@sl
غرايم ميليغان
@ar
type
label
Graeme Milligan
@ast
Graeme Milligan
@en
Graeme Milligan
@es
Graeme Milligan
@nl
Graeme Milligan
@sl
غرايم ميليغان
@ar
prefLabel
Graeme Milligan
@ast
Graeme Milligan
@en
Graeme Milligan
@es
Graeme Milligan
@nl
Graeme Milligan
@sl
غرايم ميليغان
@ar
P1006
P214
P244
P1006
P106
P21
P213
0000 0000 8279 6698
P214
P244
P31
P734
P735
P7859
lccn-n88179754